Logo
JNJ logo
Johnson & Johnson
JNJ
144.47 (0.00%) 0.00
347.83(B)
Health Care
Pharmaceuticals
Johnson & Johnson together with its subsidiaries researches develops manufactures and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas such as immunology including rheumatoid arthritis psoriatic arthritis inflammatory bowel disease and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience consisting of mood disorders neurodegenerative disorders and schizophrenia; oncology such as prostate cancer hematologic malignancies lung cancer and bladder cancer; cardiovascular and metabolism including thrombosis diabetes and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers wholesalers distributors hospitals and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips knees trauma spine sports and other; surgery portfolios comprising advanced and general surgery technologies as well as solutions for breast aesthetics ear nose and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers hospitals and retailers as well as physicians nurses hospitals eye care professionals and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick New Jersey.
Holdings:
Shares:
Cost basis:

Johnson & Johnson (JNJ) price target and intrinsic value estimate

JNJ's fair price estimate is $184.6

This valuation is based on a fair P/E of 19.5 and EPS estimates of $9.46

The median analyst price target for JNJ is $175.0.

Analyst price targets range from $155.0 to $215.0

Is JNJ overvalued or undervalued?

JNJ is currently trading at $144.47

JNJ is undervalued by 22% using the pevaluation method.

JNJ is undervalued by 17% compared to median analyst price targets.

Do you agree with this valuation?

Valuation

PEvaluation

Low $138.5
Median $184.6
High $230.8
Fair P/E
Margin of safety

Analyst valuation

Low $155.0
Median $175.0
High $215.0
Strong Buy3
Buy8
Hold13
Sell0
Strong Sell0

Discounted cash-flow

TTM FCFFCF est.Growth FCFTerminal FCF
10%
5%
5y
10%
Shares outstan...ROICRevenue growthDebt/FCFAssets/Liabili...
Economic moat: Wide
None/narrowMediumWideVery wide

Overview

Market data

Market cap:$347.83(B)
Enterprise value:$363.28(B)
Total Equity:$70.16(B)
Shares outstanding:2.41(B)
Div. yield:3.36%
P/S:3.97
P/E:23.68
P/FCF:17.16
P/B:4.96
EPS:$6.1
FCF per share:$8.4
Dividend per share:$4.9

Income (TTM)

RevenueGrossNet
Revenue$87.70(B)
Gross profit$60.85(B)
EBITDA$30.05(B)
Net income$14.68(B)
Gross margin69.4%
Net margin16.7%

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$178.29(B)
Total liabilities$108.13(B)
Cash & Short-term inv.$20.30(B)
Long-term debt$31.29(B)
Debt issued$19.93(B)
Debt repaid$-11.54(B)

Cash flow (TTM)

CFOCFICFF
FCF$20.27(B)
CapEx$-4.87(B)
Dividends paid$-11.70(B)
Stock issued$901.00(M)
Stock repurchased$-2.37(B)
Stock-based comp.$1.12(B)

Future Growth

Revenue

CAGR: 3.4%
FY+1$88.78(B)
FY+2$91.35(B)
FY+3$94.69(B)
FY+4$97.44(B)
FY+5$101.59(B)

Net Income

CAGR: 4.4%
FY+1$24.15(B)
FY+2$25.65(B)
FY+3$26.95(B)
FY+4$27.18(B)
FY+5$28.72(B)

EPS

CAGR: 5.0%
FY+1$9.96
FY+2$10.62
FY+3$11.18
FY+4$11.39
FY+5$12.10

FCF per share

CAGR: 12.7%
FY+1$10.22
FY+2$11.42
FY+3$12.98

Similar Companies

Historical Financials

Showing limited histrical data. Access 10+ years of financials now! Upgrade
YearlyQuarterly
Income
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
RevenueNet IncomeCOGSGross ProfitTotal OpEx.R&DSG&AOperating IncomeInterest ExpenseInterest IncomePre-tax incomeIncome tax
Cash flow
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
FCFCFONet IncomeD&AStock-based Comp.CFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Total AssetsTotal LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EGoodwillCurrent liabilitiesAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Shares outstanding
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Shares (Basic)Shares (Diluted)
Per share data
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
EPS (Basic)EPS (Diluted)FCF/ShareDividend/ShareBook value/Share
Ratios
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
P/EP/FCFP/BP/SEV/EarningsEV/FCFDebt/EquityPayout ratio
Margins
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Net Income MarginOperating MarginGross MarginEBITDA MarginFCF Margin
Returns
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
ROICROAROCEROE
Market Cap.
FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Market Cap.